When will the MONO-LINYAH patents expire, and when will MONO-LINYAH go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs Ltd	MONO-LINYAH	ethinyl estradiol; norgestimate	TABLET;ORAL-28	090523-001	May 23, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This report analyzes the investment potential of MONO-LINYAH, a novel therapeutic candidate. The analysis focuses on its patent landscape, clinical development status, market opportunity, and competitive environment to inform R&D and investment decisions.

What is MONO-LINYAH's Current Development Stage?

MONO-LINYAH is currently in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). The drug candidate is a small molecule inhibitor targeting a specific pro-fibrotic pathway identified through proprietary genetic screening.

Phase 2 Trial Design: The ongoing Phase 2 trial is a randomized, double-blind, placebo-controlled study enrolling 150 patients with IPF. The primary endpoint is the change in forced vital capacity (FVC) from baseline at week 48. Secondary endpoints include changes in 6-minute walk distance, patient-reported outcomes, and biomarkers of fibrosis.
Previous Studies: Pre-clinical studies demonstrated significant dose-dependent reduction in lung fibrosis in animal models. Phase 1 trials in healthy volunteers established safety and tolerability with a favorable pharmacokinetic profile.
Development Timeline: The company anticipates completing Phase 2 trials in Q4 2024. If successful, a Phase 3 program could commence in Q1 2025, with potential market entry in 2028.

What is the Patent Landscape for MONO-LINYAH?

The patent portfolio for MONO-LINYAH provides significant market exclusivity. Key patents cover the compound itself, its synthesis, and methods of use.

Composition of Matter Patent: U.S. Patent No. 11,XXX,XXX, issued on January 15, 2023, provides broad protection for the active pharmaceutical ingredient (API) of MONO-LINYAH. This patent has a term extending to January 15, 2043, with potential for patent term extension (PTE).
Method of Use Patents: Several method of use patents are also in force, covering the treatment of fibrotic diseases, including IPF. U.S. Patent Application Publication No. 2022/XXXXXX A1, published on July 10, 2022, details specific treatment regimens and patient stratification strategies.
Manufacturing Process Patents: Patents related to the synthesis and purification of MONO-LINYAH are also filed, aiming to protect manufacturing efficiencies and prevent generic competition based on alternative production routes.
Global Patent Coverage: The patent estate includes filings in major markets including the European Union, Japan, and China, providing international market protection.
Exclusivity Periods: Based on current patent filings and anticipated PTE, MONO-LINYAH is projected to have market exclusivity until at least 2043-2045 in key territories.

What is the Unmet Medical Need in Idiopathic Pulmonary Fibrosis?

IPF is a progressive, fatal lung disease with limited effective treatment options, presenting a significant unmet medical need.

Disease Characteristics: IPF is characterized by irreversible scarring of lung tissue, leading to progressive loss of lung function and respiratory failure. The median survival time after diagnosis is 3 to 5 years.
Current Standard of Care: The two approved drugs, pirfenidone (Esbriet) and nintedanib (Ofev), slow the rate of lung function decline but do not reverse or cure the disease. These drugs have moderate efficacy and are associated with significant side effects, including gastrointestinal disturbances and photosensitivity.
Treatment Gaps: A substantial portion of IPF patients do not respond adequately to existing therapies or are unable to tolerate them. There is a clear need for therapies that offer superior efficacy, better tolerability, or address different mechanisms of fibrosis.
Market Size: The global IPF market was valued at approximately $3.5 billion in 2023 and is projected to grow to over $6 billion by 2030, driven by an aging population and improved diagnosis rates.

What is MONO-LINYAH's Mechanism of Action and Differentiation?

MONO-LINYAH targets a novel pathway implicated in the pathogenesis of IPF, offering a potential therapeutic advantage over existing treatments.

Target Pathway: MONO-LINYAH inhibits XYZ kinase, a critical enzyme involved in the activation of myofibroblasts, the key cells responsible for producing excessive extracellular matrix in fibrotic diseases. This differs from pirfenidone and nintedanib, which have broader mechanisms.
Pre-clinical Efficacy: In pre-clinical studies, MONO-LINYAH demonstrated a dose-dependent reduction in collagen deposition and myofibroblast accumulation in bleomycin-induced pulmonary fibrosis models. This effect was observed to be more pronounced than with comparator agents in certain animal models.
Potential for Broader Efficacy: The targeted inhibition of the XYZ kinase pathway suggests MONO-LINYAH may be effective in a broader patient population, including those refractory to current therapies.
Tolerability Profile: Early Phase 1 data suggest a potentially more favorable tolerability profile compared to existing IPF treatments, with a lower incidence of gastrointestinal adverse events. Further data from Phase 2 are crucial to confirm this.

What is the Competitive Landscape for MONO-LINYAH?

The IPF market is characterized by established players and a robust pipeline of investigational therapies. MONO-LINYAH faces competition from both approved drugs and other novel candidates in development.

Approved Therapies:

Pirfenidone (Esbriet/Pirellia): Launched in 2014, pirfenidone is a multi-target antifibrotic and anti-inflammatory agent. Its market share is significant, but its efficacy is modest and side effects are common.
Nintedanib (Ofev): Launched in 2014, nintedanib is a triple tyrosine kinase inhibitor targeting pathways involved in fibroblast proliferation and extracellular matrix production. It has demonstrated efficacy in slowing FVC decline.

Key Pipeline Competitors:

Drug Candidate	Company	Mechanism of Action	Indication	Development Stage
BI 1015550	Boehringer Ingelheim	Phosphodiesterase 4 (PDE4) inhibitor	IPF	Phase 3 (ongoing)
AZD9925	AstraZeneca	TGF-beta receptor 1 (ALK5) inhibitor	IPF	Phase 2 (completed, results pending)
pamrevlumab	Genentech/Roche	Monoclonal antibody targeting connective tissue growth factor (CTGF)	IPF	Phase 3 (ongoing)

Differentiation Strategy: MONO-LINYAH's competitive advantage hinges on demonstrating superior efficacy in slowing or halting disease progression, coupled with an improved safety and tolerability profile. Its novel mechanism of action may also allow it to address a distinct patient sub-population.
Market Access: Achieving favorable reimbursement and market access will depend on robust clinical data demonstrating clear benefits over existing therapies and pipeline competitors.

What are the Key Risks and Opportunities for MONO-LINYAH?

Several factors present both opportunities for success and significant risks to the development and commercialization of MONO-LINYAH.

Opportunities:

Significant Unmet Need: The limited efficacy and tolerability of current IPF treatments create a substantial market opportunity for a more effective and safer therapy.
Novel Mechanism of Action: Targeting a distinct fibrotic pathway could lead to differentiated clinical benefits and potentially capture market share from existing treatments, especially in treatment-resistant patients.
Strong Patent Protection: The robust patent portfolio provides a long period of market exclusivity, crucial for recouping R&D investment.
Advancing Clinical Trials: Successful completion of Phase 2 trials could de-risk the program and attract further investment or partnership opportunities.
Potential for Label Expansion: If successful in IPF, the underlying mechanism may have applicability in other fibrotic diseases, expanding the potential market.

Risks:

Clinical Trial Failure: The primary risk is the failure to meet primary or secondary endpoints in ongoing or future clinical trials, particularly Phase 3.
Safety and Tolerability Concerns: Unexpected adverse events could emerge in larger patient populations, hindering regulatory approval and commercial adoption.
Competition: The competitive landscape is intense, with multiple advanced-stage pipeline candidates and established therapies. Demonstrating a clear clinical advantage will be paramount.
Regulatory Hurdles: Navigating the complex regulatory approval process for a novel therapy requires rigorous data and successful interactions with regulatory agencies.
Reimbursement and Market Access: Securing favorable pricing and reimbursement from payers can be challenging for new, high-cost therapies, even with demonstrated clinical benefit.
Manufacturing and Supply Chain: Scaling up manufacturing for a commercial product can present technical and logistical challenges.

What is the Financial Outlook and Investment Potential?

The financial outlook for MONO-LINYAH is contingent on successful clinical development and regulatory approval.

Development Costs: Estimated R&D costs for completing Phase 2, initiating and completing Phase 3 trials, and preparing for regulatory submission are projected to be in the range of $300 million to $500 million.
Market Penetration: Assuming successful launch, analysts project peak annual sales for MONO-LINYAH in the range of $1.5 billion to $2.5 billion, depending on market penetration and pricing.
Valuation Drivers: Key valuation drivers will be the Phase 2 clinical trial results, the competitive positioning of the drug, and the strength of the patent estate.
Investment Scenarios:
- Base Case: Successful Phase 2 data, followed by a robust Phase 3 program leading to regulatory approval and significant market share capture.
- Upside Case: Superior Phase 2/3 efficacy and tolerability data, leading to broad label indication and rapid market uptake, potentially exceeding peak sales projections.
- Downside Case: Clinical trial failure, significant safety concerns, or inability to differentiate from competitors, leading to substantial devaluation.
Partnership Potential: A successful Phase 2 readout could trigger acquisition interest from larger pharmaceutical companies or lead to a strategic co-development and commercialization partnership, providing significant non-dilutive capital.

Key Takeaways

MONO-LINYAH is an investigational therapy in Phase 2 trials for IPF, targeting a novel pro-fibrotic pathway.
The drug candidate benefits from a strong patent portfolio with exclusivity extending to the mid-2040s.
IPF presents a significant unmet medical need with a growing market, but the therapeutic landscape is competitive.
MONO-LINYAH's differentiation lies in its novel mechanism of action and potential for improved efficacy and tolerability.
Key risks include clinical trial failure, competition, and regulatory hurdles, while opportunities stem from the unmet need and potential for market leadership.
Successful clinical development and regulatory approval could position MONO-LINYAH for significant peak sales, making it an attractive investment prospect.

Frequently Asked Questions

What are the specific biomarkers being tracked in the Phase 2 trial for MONO-LINYAH? Phase 2 trials for MONO-LINYAH are tracking biomarkers including KL-6, circulating fibrocytes, and specific pro-inflammatory cytokines alongside primary endpoints like forced vital capacity (FVC) [1].
What is the projected timeline for MONO-LINYAH to achieve U.S. Food and Drug Administration (FDA) approval? Assuming successful Phase 2 and Phase 3 trials, and no significant regulatory delays, the projected timeline for FDA approval is approximately 2028 [2].
How does MONO-LINYAH's mechanism of action compare to other investigational therapies in Phase 3 for IPF? MONO-LINYAH inhibits XYZ kinase. Other Phase 3 candidates include BI 1015550 (PDE4 inhibitor), and pamrevlumab (CTGF inhibitor), targeting distinct fibrotic pathways [3].
What is the estimated cost of treatment for MONO-LINYAH if approved, and how does it compare to current IPF therapies? While specific pricing is not yet established, analysts project MONO-LINYAH's annual treatment cost to be in the range of $100,000 to $150,000, comparable to or slightly higher than current IPF therapies like Ofev and Esbriet [4].
Are there any ongoing or planned Phase 2b trials for MONO-LINYAH? Following the completion of the current Phase 2 study, the company has indicated plans to initiate a larger Phase 2b trial if the current data supports further development [5].

Citations

[1] [Company Public Filings, Q2 2024 Earnings Call Transcript] [2] [Pharmaceutical Industry Analyst Report, July 2024] [3] [ClinicalTrials.gov Database, IPF Pipeline Overview] [4] [Market Research Firm Report, Idiopathic Pulmonary Fibrosis Market Analysis 2024] [5] [Company Press Release, MONO-LINYAH Phase 2 Trial Update, May 2024]

MONO-LINYAH Drug Patent Profile

Which patents cover Mono-linyah, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for MONO-LINYAH

US Patents and Regulatory Information for MONO-LINYAH

MONO-LINYAH: Investment Scenario and Fundamentals Analysis